In the evaluation of MCI, it is therefore important to map APOE-4 status, but in clinical practice, knowledge of APOE status usually contributes less to the diagnostic assessment than mapping cognitive function, brain imaging, and mapping markers of amyloid deposition and neuronal damage (Weiner et al., 2015). The gene discussed is APOE; the disease is amyloidosis.